Companies seeking to commercialise a probiotic product across the globe face a 'daunting task', which is why trade association the International Probitics Association (IPA) is vowing not to let up in its efforts to achieve a more consistent...
Parkinson’s disease (PD) ‘starts in the gut’ says an expert, who spoke of a study that identifies the gut-brain axis and change in microbiome environment as playing key roles in disease onset and progression.
A BASF-led study has pointed towards the use of high-concentration omega-3 in managing the consequences of non-alcoholic fatty liver disease (NAFLD), a condition that affects roughly one in five Europeans.
The Nagoya Protocol, the big changes coming for Lactobacillus classification, and how to boost your chances of success with an NDI notification were just some of the topic covered during the third annual IPA Workshop in DC.
The prime purchasing decision of fortified and nutritional products amongst the elderly remains the efficacy of the active ingredients contained within the product, according to a survey carried out by DuPont Nutrition & Health.
The translation of microbiome science into commercially viable applications remains an ongoing challenge that needs addressing before consumers are able to reap the mental and physical health benefits.
Artificial Intelligence (AI) and the microbiota have been identified as opportunities for the private sector to offer affordable nutrition to lower-income consumers, who are at a higher risk of malnutrition.
The International Probiotics Association (IPA) has urged the industry to support its efforts to bring consistency to the global regulatory landscape, so that the rules can keep pace with technology and scientific advancement.